Beyond Air Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update Revenues increased 220% to $3.7 million, compared with $1.2 million for the fiscal year ended

Air Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

increased 220% to $3.7 million, compared with $1.2 million for the fiscal year ended March 31, 2024

to report revenue of at least $1.7 million for quarter ending June 30, 2025, and introducing revenue guidance of $12-$16 million for

the full fiscal year 2026

PMA supplement for second-generation LungFit PH to FDA

distribution partnerships now provide access to markets representing over 2 billion lives, with LungFit PH actively shipping to

Europe, Australia, and the Middle East

Robert Goodman, a commercial focused seasoned healthcare executive, to the Company's Board of Directors

call at 4:30 p.m. ET today, June 17th

City, NY, June 17, 2025 - Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a

commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives

of patients, today announced its financial results for fiscal fourth quarter and year ended March 31, 2025, and provided a corporate

commercial momentum is building, and that progress is now being reflected in our topline results," said Steve Lisi, Chairman and

Chief Executive Officer. "With LungFit PH now installed and in regular use at more than 45 hospitals nationwide, awareness is accelerating.

Clinicians and administrators are increasingly recognizing the advantages of our cylinder-free system compared to conventional nitric

oxide delivery methods."

Lisi added, "Regulatory approvals and new international partnerships across Europe, the Middle East, and Asia have already driven

strong order activity, with over a dozen initial units shipped to customers in just the past few weeks. We expect to report at least

$1.7 million in revenue for the quarter ending June 30, 2025, and anticipate sustained double-digit sequential revenue growth moving

forward, leading to FY 2026 revenues expected to be in the range of $12 to $16 million."

submission of the PMA supplement to the FDA for our second-generation LungFit PH device, which we announced yesterday, could be transformative

for our business," continued Lisi. "If approved, we believe this new system will unlock significant market potential. Coupled

with our global expansion and rising brand recognition, we are entering what we believe will be an exciting and pivotal year for Beyond

Air and our shareholders."

Execution, Recent Highlights and Upcoming Milestones

Cancer - Solid Tumor Program

- Autism Spectrum Disorder (ASD) Program

Results for the Fiscal Year Ended March 31, 2025

for the fiscal year ended March 31, 2025 increased 220% to $3.7 million, compared with $1.2 million for the fiscal year ended March 31,

2024. Cost of revenue of $5.4 million was recognized for the year ended March 31, 2025, compared with $2.5 million for the year ended

March 31, 2024. Cost of revenue exceeded revenue primarily driven by depreciation of LungFit devices and one-time upgrade costs to systems.

and development expenses for the fiscal year ended March 31, 2025 were $16.9 million compared with $24.4 million for the fiscal year

ended March 31, 2024. The decrease of $7.5 million was primarily attributed to a decrease in salaries, stock-based compensation and to

a lesser extent from clinical and pre-clinical studies expenses.

general and administrative expenses for the years ended March 31, 2025 and March 31, 2024 were $26.0 million and $37.3 million, respectively.

The decrease of $11.3 million was attributed primarily to a reduction in salaries and stock-based compensation cost.

expense for the year ended March 31, 2025 was $3.9 million compared with $1.3 million for the year ended March 31, 2024. The increase

in other expense of $2.6 million was mainly due to a non-cash loss recorded upon the retirement of the Avenue Capital debt.

loss attributed to common stockholders of Beyond Air, Inc. for the year ended March 31, 2025 was ($46.6) million or a loss of ($0.69)

per share, basic and diluted, compared to a net loss attributed to common stockholders of Beyond Air, Inc. for the fiscal year ended

March 31, 2024 of ($60.2) million or a loss of ($1.82) per share, basic and diluted.

burn in the fiscal year ended March 31, 2025, excluding the impacts of financing and the extinguishment of debt, was $44.1 million.

of March 31, 2025, the Company reported cash, cash equivalents, and marketable securities of $6.9 million, which excludes the $1.0 million

payment from GETZ Healthcare that arrived after March 31, 2025, and total long-term debt outstanding of $12.2 million. Debt repayment

does not begin until October 2026. Subsequent to March 31, 2025, the Company received $2.0 million of additional financing under the

existing long-term debt agreement.

Guidance for Fiscal Year 2026:

June 17th @ 4:30 PM ET

Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous

nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The

Company has received FDA approval and CE Mark for its first system, LungFit PH, for the treatment of term and near-term neonates

with hypoxic respiratory failure. Beyond Air is currently advancing its other revolutionary LungFit systems in clinical trials for the

treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria (NTM).

Company has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism

spectrum disorder (ASD) and other neurological disorders. Additionally, Beyond Cancer, Ltd., an affiliate of Beyond Air, is investigating

ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more

information, visit www.beyondair.net.

Air's LungFit is a cylinder-free, phasic flow generator and delivery system designated as a medical device by the U.S. Food and

Drug Administration (FDA). The ventilator-compatible version of the device can generate NO from ambient air on demand for delivery to

the lungs at concentrations ranging from 1 ppm to 80 ppm. The LungFit system could potentially replace large, high-pressure NO cylinders,

providing significant advantages in the hospital setting, including greatly reducing inventory and storage requirements, improving overall

safety by eliminating NO2 purging steps, and offering other operational benefits.

can also deliver NO at concentrations at or above 80 ppm for potentially treating severe acute lung infections in the hospital setting

(e.g., COVID-19, bronchiolitis) and chronic, refractory lung infections in the home setting (e.g., NTM). With the elimination of cylinders,

Beyond Air intends to offer NO treatment in the home setting.

Air's LungFit PH is approved for commercial use in the United States, European Union, Australia, Thailand and New Zealand. Beyond

Air's other LungFit systems are not approved for commercial use and are for investigational use only. Beyond Air is not suggesting

NO use over 80 ppm or use at home.

pulmonary hypertension of the newborn (PPHN) is a lethal condition and secondary to failure of normal circulatory transition at birth.

It is a syndrome characterized by elevated pulmonary vascular resistance (PVR) that causes labile hypoxemia due to decreased pulmonary

blood flow and right-to-left shunting of blood. Its incidence has been reported as 1.9 per 1,000 live births (0.4-6.8/1000 live

births) with mortality rate ranging between 4-33%. This syndrome complicates the course of about 10% of infants with respiratory

failure and remains a source of considerable morbidity and mortality. NO gas is a vasodilator, is approved in dozens of countries to

improve oxygenation and reduces the need for extracorporeal membrane oxygenation (ECMO) in term and near-term (>34 weeks gestation)

neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction

with ventilator support and other appropriate agents.

Right Ventricular Dysfunction (RVD) (Indication not approved in the U.S.)

ventricular dysfunction is a serious medical condition where the heart's right ventricular is unable to pump enough blood through

the lungs to support the needs of the body, and its presence in critically ill patients is associated with significant morbidity and

mortality. Numerous clinical studies showed that in the peri-operative phases of cardiac surgery, inhaled nitric oxide (iNO) is effective

in decreasing pulmonary artery pressure, decreasing pulmonary vascular resistance, improving right ventricular ejection fraction, and

improving blood oxygenation in the presence of pulmonary hypertension. Consequently, iNO is an important part of acutely decreasing right

ventricular afterload for patients suffering from right ventricular dysfunction

Cancer, Ltd., an affiliate of Beyond Air, Inc., is a development-stage biopharmaceutical and medical device company utilizing (UNO via

a proprietary delivery platform to treat primary tumors and prevent metastatic disease. Nitric oxide at ultra-high concentrations has

been reported to show anticancer properties and to potentially serve as a chemosensitizer and radiotherapy enhancer. A first-in-human

study is underway in subjects with solid tumors. The Company is conducting preclinical studies of UNO in multiple solid tumor models

to inform additional treatment protocols. For more information, visit www.beyondcancer.com.

is at the forefront of developing innovative treatments for neurodevelopmental and neurodegenerative disorders. The company specializes

in creating therapies based on small molecules that cross the blood-brain barrier to regulate Nitric Oxide (NO) levels in the brain.

Preclinical studies conducted by NeuroNOS have demonstrated that NO is present at elevated levels in children with Autism Spectrum Disorder

(ASD) and adults suffering from brain-related diseases such as Alzheimer's and brain cancers. The company's research has

shown that managing NO levels in the brain is crucial for maintaining normal brain function. By leveraging this groundbreaking science,

NeuroNOS aims to bring transformative therapies to those affected by these challenging conditions, ultimately improving individuals'

lives. Through collaborations with leading research institutions and experts in the field, the company is committed to advancing medical

innovation and delivering life-changing treatments. For more information, please visit https://www.neuro-nos.com.

press release contains "forward-looking statements" concerning the potential safety and efficacy of inhaled nitric oxide

and the ultra-high concentration nitric oxide product candidate, as well as its therapeutic potential in a number of indications; and